muromonab-CD3
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00619372 | Jan → Apr 2008 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01287195 | Apr 2011 → May 2013 | ulcerative colitis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00002482 | Jun 1991 → ? | cancer of unknown primary site | St. Vincent Medical Center - Los Angeles | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00004482 | Dec 1999 → Jul 2005 | giant cell myocarditis | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00005852 | Jun 1996 → Jul 2007 | graft versus host disease, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +1 | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00186823 | Mar 2002 → Sep 2005 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia +2 | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00027443 | Aug 2001 → Jul 2007 | myocarditis | Mayo Clinic | Completed | No outcome recorded |
Also used as a comparator or background therapy in 19 trials
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | muromonab-CD3 | “Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an...” NCT00145626 ↗ |
| Known as | Anticd3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201608 ↗ |
| Known as | L04AA02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201608 ↗ |
| Known as | Macs gmp cd3 pure | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201608 ↗ |
| Known as | MOAB OKT3 | “Anti-CD3 Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271” NCT00002482 ↗ |
| Known as | Muromomab | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201608 ↗ |
| Known as | Muromonab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00566696 ↗ |
| Known as | OKT-3 | “Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an...” NCT00145587 ↗18“Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted...” NCT00143559 ↗ “Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3.” NCT00152113 ↗ “Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3.” NCT00186823 ↗ “Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan.” NCT00145613 ↗ “Anti-CD3 Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271” NCT00002482 ↗ “the other arm utilized negative selection with the anti-CD3 antibody OKT-3” NCT00186823 ↗ “anti-CD3 monoclonal antibody (OKT3)” NCT00004022 ↗ “OKT-3 (5mg/d) from day -5 to day +3” NCT01220544 ↗ “OKT3” NCT00145626 ↗ |
| Known as | Orthoclone okt3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201608 ↗ |
| Action | Deplete | “Muromonab-CD3 has been shown to reduce the number of lymphocytes” NCT00027443 ↗ |
| Modality | Monoclonal antibody | “Anti-CD3 Murine Monoclonal Antibody” NCT00002482 ↗ |
| Route | Intravenous | “muromonab-CD3 IV once daily for 10 days” NCT00004482 ↗ |